Therapeutic | Obinutuzumab |
Target | MS4A1 |
Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS |
Light Chain | DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK |
100% seqID Fv Structure | 3pp3 [Fvs: HL, IK], 3pp4 [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3pp3 [Fvs: HL, IK] |
100% seqID Structure | 3pp4 [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | GlycoMAb Technology |
INN Year Proposed | 2008 |
INN Year Recommended | 2011 |
Companies Involved | GLYCART Biotechnology, Biogen Idec, Chugai Pharmaceutical, Dana-Farber Cancer Institute, Genentech, Lymphoma Academic Research Organisation, Nippon Shinyaku, OHSU Knight Cancer Institute, Pharmacyclics, Polish Myeloma Consortium, Roche, Thomas Jefferson University, University of Heidelberg, University of Leeds |
Conditions Approved | Chronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin's lymphoma |
Conditions Active | Diffuse large B cell lymphoma, CNS cancer, Graft-versus-host disease, Lupus nephritis, Mantle-cell lymphoma, Waldenstrom's macroglobulinaemia |
Conditions Discontinued | Primary biliary cirrhosis |
Notes | Obinutuzumab and Afutuzumab are the same mAb |